Skip to Content

Clinical Trial Details

Celebrex Use for Colon Cancer

A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Objective

The study will compare four different “arms” of treatment. FOLFOX consists of the combination of these chemotherapy agents: 5-fluorouracil (also called 5-FU), leucovorin and oxaliplatin. For groups 1 and 2 - Patients will receive an intravenous (through the vein in your arm) treatment of FOLFOX every other week for a total of 12 treatments or 24 weeks. Group 1 will also receive a placebo pill. Group 2 will also receive a celecoxib pill. Groups 3 and 4 – Patients will receive an intravenous treatment of FOLFOX every other week for a total of six treatments or 12 weeks. Group 3 will also receive a placebo and group 4 will receive celoxib.

IRB Protocol Number
HIC 10-10 CALGB 80702
Principal Investigator(s)
Charles Catcher, MD

Clinical Trial Categories

  • Colorectal Cancer
Sponsor(s)
National Cancer Institute
Contact
Margaret White, RN OCN, CC at 603-232-8908
How to Participate

Inclusion Criteria:

  • Patients who have colon cancer, which has been surgically removed, but has spread to the lymph nodes may be eligible for this study.

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000